US Patent Number
The present invention provides, among other things, oligonucleotide modulators of human 5'-HT2C receptor (HTR2C) and improved methods and composition for treating HTR2C-related diseases, disorders or conditions based on such modulators. In particular, oligonucleotides modulators according to the invention target specific regions in the Exon V/Intron V junction of the human HTR2C pre-mRNA and drive expression of HTR2C Vb splice isoform, leading to increased generation of non-edited strong HTR2C receptor and enhanced serotonin receptor activity.
Shire Human Genetic Therapies, Inc., Lexington, MA (US); University of Kentucky, Lexington, KY (US)
Stamm, Stefan; Shen, Manli; and Josiah, Serene, "Antisense Oligonucleotide Modulators of Serotonin Receptor 2C and Uses Thereof" (2017). Molecular and Cellular Biochemistry Faculty Patents. 23.